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Introduction
Although pregnancy is typically a joyous event, it can pose sig-
nificant risk to the mother and infant in the setting of type 1 or
type 2 diabetes, also referred to as pregestational diabetes.
Studies from UK and Ireland reveal poor outcomes for women
with diabetes in pregnancy including a congenital malformation
rate twice that of the background population, a 5-fold increased
risk of stillbirth and a 3-fold increased risk of perinatal mortality
and caesarean delivery.1–3 A further, emerging challenge is the
increasing prevalence of type 2 diabetes in pregnancy associated
with the concurrent rise in obesity. These women are more com-
monly from ethnic minorities and although predominantly cared
for in community settings with minimal access to specialist care,
they experience similar adverse outcomes to those with type 1
diabetes and are a particularly vulnerable group.4,5 Unfortunately,
we have not achieved the target of the Saint Vincent declaration
which in 1989 called for outcomes equal to that of the non-
diabetic pregnancy within 5 years.6 On a more positive note,
structured clinical care programs providing coordinated,
evidence-based care to these women before, during and after preg-
nancy have demonstrated improved clinical outcomes.4,7 This
article focuses on optimal management of women with type 1 and
type 2 diabetes during this important time. Unless otherwise speci-
fied the information provided relates to both type 1 and type 2 dia-
betes. Gestational diabetes, typically a transient abnormality of
glucose intolerance during pregnancy is not discussed.
Prepregnancy care: an opportunity not to be missed
The risk of certain adverse outcomes including malformations
and perinatal mortality is related to poor glycaemic control in
early pregnancy.8 Intervention before the pregnancy is neces-
sary to ensure optimal glycaemic control throughout the time of
conception and this critical early stage. The value of a ‘prepreg-
nancy’ clinic was first demonstrated almost 30 years ago and it
is now accepted practice that preconception counselling is
provided to all women with diabetes who are considering
pregnancy.9,10 Typically women attending a centre for
prepregnancy care are reviewed at 1–3 monthly intervals. The
importance of avoiding an unplanned pregnancy should be ex-
plained and contraception advised until treatment goals are
achieved.
A full medication review should take place and any medica-
tions unsuitable for pregnancy such as angiotensin converting
enzyme inhibitors or statins should be discontinued.4 With the
exception of metformin, all hypoglycaemic agents should be
discontinued. If necessary, smoking and alcohol cessation ad-
vice should be provided. Retinal evaluation should take place
and if therapy is required, pregnancy deferred until its comple-
tion. Satisfactory blood pressure control is necessary (<130/
80 mmHg) and if there is evidence of renal dysfunction, nephrol-
ogy review is recommended.9 Thyroid status must be assessed
and managed at this time. Hypothyroidism may reduce fertility,
increase the risk of miscarriage and impair foetal brain develop-
ment if untreated.9 All women require a dietician review and
those with a body mass index (BMI) above 27 kg/m2 should be
offered advice on how to lose weight. Prior to discontinuing
contraception, folic acid 5 mg once daily is advised until 12
weeks gestation.3 Although there is no evidence of a clinical
benefit for this higher dose, several advisory groups have made
this recommendation based on a theoretical benefit in reducing
the increased risk of neural tube defects associated with dia-
betes mellitus in pregnancy.2,3,9
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Women on insulin should be treated with a multiple daily
injection (MDI) regimen or continuous subcutaneous insulin
infusion (CSII) in preference to split-dose, premixed insulin.9
The rapid-acting insulin analogues aspart and lispro are safe
and commonly used in pregnancy.3,11 Newer, long-acting ana-
logues also appear safe for use in pregnancy and have begun to
replace the traditionally used isophane insulin in clinical prac-
tice.12 Detemir in particular, is approved for use in pregnancy
and a recent study indicates that it does not cross the human
placenta.13 Regular capillary blood glucose monitoring must
take place and both pre- and postprandial levels are required.
The 2015 draft National Institute for Health and Care Excellence
(NICE) guidelines advise women with diabetes who are planning
to become pregnant to maintain their HbA1c below 6.5%
(48 mmol/mol) as this is associated with a reduction in congeni-
tal anomalies to close to that seen in the background popula-
tion.3 The major limitation to tight glycaemic targets is
hypoglycaemia and instruction on its management including
use of glucagon should be provided to the patient and/or family
members. Women with type 1 diabetes should have the ability
to test for ketones (urinary or capillary) should they become un-
well or hyperglycaemic.
Attendance at prepregnancy care is associated with a reduc-
tion in congenital anomalies, perinatal mortality and maternal
HbA1c in the first trimester of pregnancy.14 These reductions
are applicable to women with both type 1 and type 2 diabetes.
Unfortunately, attendance at prepregnancy care is not universal
and therein lies a challenge in getting advice to those who need
it in an acceptable and understandable form. Of concern is the
Confidential Enquiry into Maternal and Child Health survey
which revealed that only 17% maternity services in the United
Kingdom actually provided structured multidisciplinary precon-
ception care.5 Murphy et al. demonstrated that a regionalized
approach to preconception counselling and prepregnancy care
improved pregnancy preparation and reduced risk of adverse
pregnancy outcomes; however, women with type 1 diabetes
were still more likely to have had documented preconception
counselling (54 vs. 32% with type 2 diabetes). Despite improved
counselling only 27% women attended prepregnancy care clin-
ics with significantly more women with type 1 diabetes repre-
sented (30 vs. 20%). Socioeconomic status appears to be a major
determinant as women who attended prepregnancy care were
more likely to be white and less likely to live in a deprived area,
smoke cigarettes and to be overweight or obese.4 Although
women with type 1 diabetes are more likely to have suboptimal
preconception control, attendance at prepregnancy care pro-
grams is particularly poor among women with type 2 dia-
betes.4,5 Cited barriers to engaging with preconception care
include negative experiences with health professionals, lack of
information and work commitments.15,16
Antenatal care
When the woman becomes pregnant, immediate contact with a
joint diabetes and antenatal clinic should be facilitated. This
concept of a combined clinic allows the diabetes physician to be
involved in a meaningful way as the pregnancy progresses.17
Although these clinics may differ in terms of structure, it is
important that women are reviewed every 1–2 weeks by the
diabetes team and a system for diabetes consultation (e.g. tele-
phone helpline) is available on demand. Capillary blood glucose
levels are monitored before and either 1 or 2 h after the start of
each meal, before bed and if necessary overnight. Targets must
be individualized and safe, however a fasting glucose of
<5.3 mmol/l and 1-h post prandial of <7.8 mmol/l are reason-
able goals. HbA1c does not reliably reflect changes in mean
blood glucose in pregnancy, particularly in the second and third
trimesters, but higher levels (HbA1c >6.0–6.5%) may still be
used as marker of poor glycaemic control and a pregnancy
which is at increased risk of poor outcome.18 Hypoglycaemia is
a common problem in the first trimester and is often associated
with a diminished awareness. The situation changes by 16
weeks and increasing insulin resistance requires regular upti-
tration of insulin to achieve euglycaemia with prepregnancy in-
sulin doses often doubling by 30 weeks gestation.17 Recurrent
hypoglycaemia affects women with type 1 diabetes more fre-
quently than those with type 2, likely related to the fact that
women with type 1 diabetes have longer diabetes duration,
more hypoglycaemia unawareness and that not all women with
type 2 diabetes require insulin therapy.5 The importance of ke-
tone testing and hypoglycaemic management should be
reemphasized during the pregnancy. If there is a suspicion or
diagnosis of diabetic ketoacidosis during pregnancy, this must
be treated as an emergency and the woman admitted to a crit-
ical care area with immediate specialist review.3
Excessive weight gain during pregnancy is now established as
an independent risk factor for adverse pregnancy outcomes.19
We advocate the use of 2009 Institute of Medicine recommenda-
tions to advise on appropriate gestational weight gain as per BMI
at booking visit and the provision of additional support to facili-
tate lifestyle changes to assist adherence (Table 1).20 In general,
physical activity should be encouraged and while some dietary
modifications are necessary to prevent large increases in blood
glucose, a balanced diet is advised overall. Pregnant women with
diabetes should be referred to a dietician specializing in preg-
nancy. Sugars and simple carbohydrates should be eliminated
with ideal carbohydrate sources including fresh vegetables, some
fruits and whole grains.21 There is no definitive evidence for the
optimal proportion of carbohydrate in the diet of women with
diabetes and more research is needed into the relationship
between maternal dietary intake both in terms of gestational
weight gain and postprandial glucose control in these women.9
Furthermore, there are no randomized trials evaluating the
effects of a modified diet for those women with diabetic nephrop-
athy in pregnancy.4
Progression of diabetic retinopathy during pregnancy is well
described in both type 1 and type 2 diabetes. Various contribu-
ting factors are identified including pre-existing retinopathy,
increasing duration of diabetes and higher blood pressure in
early pregnancy.22 Although associations between rapid de-
clines in HbA1c during pregnancy and deterioration in retinop-
athy status have been identified, the presence of retinopathy
should not be considered a contraindication to rapid opti-
mization of glycaemic control if necessary. Instead, the authors
advise identification and close monitoring of those women at
high risk of deterioration. NICE recommend retinal assessment
by digital imaging following the first antenatal appointment
and again at 28 weeks if the first assessment is normal. If any
diabetic retinopathy is present, an additional retinal assess-
ment should be performed at 16–20 weeks.3
If unknown, renal status should be established at the book-
ing visit. Nephrology review is necessary if serum creatinine is
abnormal (120 mmol/l or more) or if total protein excretion ex-
ceeds 2 g/day. Renal function is closely linked with blood pres-
sure and the latter must be monitored closely during
pregnancy. Specialist care is essential as aggressive manage-
ment of hypertension often requires multiple agents and is
associated with improved pregnancy outcomes.23 Calcium
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channel blockers such as nifedipine are commonly used while
beta blockers such as labetalol may be used with caution.
Methyldopa also has proven safety during embryogenesis and is
also suitable, although it is commonly associated with maternal
side effects of postural dizziness.17
Women with diabetes in pregnancy require additional foetal
monitoring. As many women with diabetes have menstrual
irregularities making dating based on last menstrual period less
accurate, viability of pregnancy and gestational age should be
confirmed on ultrasound scan at 7–9 weeks.3 A four-chamber
view of the foetal heart and outflow tracts must be offered at
18–20 weeks with referral to a specialist centre if necessary.
Monitoring of foetal growth and amniotic fluid volume is
advised every 4 weeks from 28–36 weeks. When a macrosomic
foetus is diagnosed on ultrasound, a specialist decision regard-
ing the optimal method and timing of delivery is necessary. If a
woman is treated with insulin and steroids are required for foe-
tal lung maturation, additional insulin is necessary. This is typ-
ically administered intravenously and infusion rates adjusted
according to the glucose level on an hourly basis. Each centre
should have a clear protocol in this regard.
Labour and delivery
This is an exciting time for the woman and her family and it is
important that clear protocols are in place in the delivery unit
to ensure the process runs smoothly. Home births are not
advised. Women with diabetes-related complications (particu-
larly autonomic neuropathy) may benefit from an anaesthetic
consultation in the third trimester to ensure the birth plan is ap-
propriate. Pregnant women with diabetes who have a normally
grown foetus should be offered elective birth through induction
of labour or by elective caesarean section (if indicated) between
37 weeksþ 0 days and 38 weeksþ 6 days of pregnancy.3 The
presence of pregestational diabetes alone is not an indication
for caesarean delivery. As maternal hyperglycaemia during la-
bour and delivery is associated with neonatal hypoglycaemia
and foetal distress, tight glycaemic control is necessary.3 This
is traditionally achieved using intravenous insulin and dex-
trose infusions to maintain maternal blood glucose levels at
4–7 mmol/l, although CSII is increasingly used.
All neonates born to mothers with diabetes in pregnancy
require review by a neonatologist on delivery. The maternity unit
must have the facility to provide advanced neonatal care on de-
mand at all times should the need arise. Unless there is a compli-
cation, neonates should go to the postnatal ward with their
mother on delivery. Feeding should take place as soon as possible
after birth and at regular intervals thereafter. Blood glucose test-
ing should be carried out routinely in babies of women with dia-
betes at 2–4 h after birth to exclude neonatal hypoglycaemia. This
should take place earlier if there are clinical signs of
hypoglycaemia such as severe irritability or seizure-like activity.
If blood glucose values are below 2.0 mmol/l on two consecutive
readings despite feeding or if there are abnormal clinical signs,
additional measures such as intravenous dextrose or tube feed-
ing may be necessary.3 Other neonatal complications occurring
more frequently in offspring of mothers with diabetes include re-
spiratory distress, jaundice and hypocalcaemia.
Postpartum care
Typically women revert to their prepregnancy insulin doses
post delivery; however, a further reduction of 25% may be ne-
cessary if breastfeeding is established. Breastfeeding should be
encouraged when possible as it may facilitate postpartum
weight loss along with its well-established nutritional and im-
munological benefits for the infant. Women should be advised
regarding the need to monitor glucose levels carefully while
breastfeeding and additional carbohydrate snacks are often
required to avoid hypoglycaemia. Metformin is deemed to be
safe while breastfeeding but it must be noted that there is not a
marketing authorization for this indication in UK.3
Glibenclamide (glyburide) is also used in clinical practice in the
management of diabetes while lactating and while there is
strong evidence for its safety, information on its excretion in
breast milk is limited. This information should be explained to
the mother before initiating treatment. Other oral or injectable
hypoglycaemic agents are contraindicated while breastfeeding.
The importance of planning further pregnancies and the use
of contraception in intervening periods should be reviewed.
Women with diabetes can use oral contraceptives provided
there are no standard contraindications to their use. Women’s
choice of contraception should be based on their own prefer-
ences and risk factors.3 Women with type 2 diabetes are less
likely to receive postnatal contraceptive advice than those with
type 1 and this may be due to language difficulties and per-
ceived differences in cultural attitudes.5 If appropriate, women
should be supported to achieve interpregnancy weight loss in
order to reduce obesity-related pregnancy complications in sub-
sequent pregnancies. Finally, as postpartum thyroiditis is more
common in women with diabetes, screening thyroid function
tests should take place at 3 and 6 months postpartum.9
Emerging technologies for optimal glucose control
A randomized controlled trial (RCT) in 322 type 1 diabetes preg-
nancies, demonstrated that even in an optimal RCT setting
Table 1. Institute of medicine guidelines for gestational weight gain
Pregestational
BMI category
BMI, kg/m2 Recommended
total weight
gain, kg
Recommended
mean weight gain
(kg/wk): Trimesters
2 and 3
Underweight <18.5 12.5–18.0 0.51 (0.44–0.58)
Normal weight 18.5–24.9 11.5–16.0 0.42 (0.35–0.50)
Overweight 25.0–29.9 7.0–11.5 0.28 (0.23–0.33)
Obese 30.0 5.0–9.0 0.22 (0.17–0.27)
Table 2. Key points
General:
 Pre-existing diabetes is associated with an increased risk of ad-
verse pregnancy outcomes
 Engagement with a prepregnancy care program is essential.
 Antenatal care should take place in a joint diabetes and antenatal
clinic.
Type 1 diabetes:
 Increased risk of hypoglycaemia (particularly first trimester).
 All women should have the ability to test for ketones.
Type 2 diabetes:
 Less likely to engage with prepregnancy care and receive appropri-
ate retinal screening.
 Weight loss pre- and postpregnancy should be facilitated as
necessary.
 Other than metformin, oral and injectable hypoglycaemic agents
are contraindicated.
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(excluding women with HbA1c >8%), two out of three infants
had at least one diabetes-related complication.24 These data
suggest that MDI injections, even using new generation insulin
analogues, are inadequate for optimal neonatal health out-
comes. The 2012–13 National Pregnancy in Diabetes Audit
showed that only 5% of women with type 1 diabetes achieve the
NICE glucose control target of HbA1c <6.1% and <25% achieve a
booking HbA1c <7%.25 The sustained lack of improvement in
maternal glucose control and perinatal outcomes, particularly
in type 1 diabetes pregnancy has prompted increased focus on
the role of new technologies to optimize glycaemic control be-
fore and during pregnancy.
Outside pregnancy, insulin pump therapy (CSII) can improve
glucose control, reduce risk of severe hypoglycaemia and im-
prove quality of life with 20% pregnant women using CSII
across the UK.25,26 Despite the theoretical advantages of CSII,
there is currently little evidence supporting routine use of CSII
in pregnancy. A meta-analysis of six studies (107 CSII vs. 106
MDI) showed comparable glucose control and pregnancy
outcome.27 These studies were conducted over 20 years ago,
with very small sample sizes (18 women per arm) and
lacked power to detect differences in infant outcomes. Results
from observational series of CSII versus MDI (mostly retrospect-
ive with selection biases) are conflicting, with some but
not all, suggesting lower HbA1c levels. Most suggest that CSII
is safe but inadequate for optimal maternal/foetal out-
comes.28,29 Some suggest that for optimal efficacy, CSII works
best when combined with real-time continuous glucose moni-
toring (CGM).
The 2015 draft NICE guidelines advise considering CGM for
pregnant women who have problematic severe hypoglycaemia
(with or without impaired awareness of hypoglycaemia) or
women with unstable blood glucose levels or to gain informa-
tion about variability in blood glucose.3 The CGM devices avail-
able include traditional retrospective/professional (Medtronic
Ipro2) and real-time CMG (Dexcom G4, Medtronic Enlite 2,
Navigator 2). A recent innovation is the FreeStyle Libre Flash
Glucose Monitoring System which represents an intermediate
step between finger-stick glucose testing and real-time CGM. It
can be worn for up to 14 days and does not require finger-stick
tests for calibration, which could replace finger-stick glucose
testing for women on MDI.
The future for diabetes technology looks optimistic. Ongoing
trials (GlucoMOMS and CONCEPTT) will determine the clinical
impact of retrospective and real-time CGM in type 1 diabetes
pregnancy. Others are investigating the role of closed-loop
insulin delivery, combining real-time CGM with CSII using a
computer algorithm, with preliminary feasibility studies
suggesting that this could provide consistently safe effective
glucose control for many women with type 1 diabetes.30
Summary
Pregestational diabetes is a common medical complication of
pregnancy and preconception planning is an essential compo-
nent of care for affected women of childbearing age. Once preg-
nant, structured care in a multidisciplinary team setting is
necessary to ensure optimal outcomes. Although significant
progress has been made, these women and their offspring re-
main to have a significantly elevated risk of multiple adverse
complications. Structured programmes using information tech-
nology and enabling access to novel technologies may facilitate
our goal of ensuring an outcome closer to that of a pregnancy
unaffected by diabetes.
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